Work

Preserved antibody responses to COVID-19 vaccination and lower odds of developing COVID-19 in adults with severe asthma

Year: 2024

Type: article

Abstract: Studies show that patients with severe asthma (SA) may be at a higher risk of severe coronavirus disease 2019 (COVID-19).1 Treatment of SA includes high-dose inhaled corticosteroids (H-ICSs), which has not been shown to affect postvaccination antibody titers against SARS-CoV-2 spike protein.2 Between 20% and 60% of patients with SA worldwide are dependent on maintenance oral corticosteroids (mOCSs),3 which in some autoimmune diseases lead to impaired vaccine immunogenicity.4 Many patients with SA receive biologics targeting type-2 inflammation.

Source: The Journal of Allergy and Clinical Immunology In Practice

DOI: 10.1016/j.jaip.2024.05.026

Authors: Hitasha Rupani, Diane Edwards, Rekha Chaudhuri, Steven Smith, David J. Jackson, Andrew Hearn, Jennifer Richards, Helen Moyses, Ramesh J. Kurukulaaratchy, Hans Michael Haitchi, Michael R. Edwards, Sebastian L. Johnston, Ratko Djukanovic

Institutions: University Hospital Southampton NHS Foundation Trust, NIHR Southampton Respiratory Biomedical Research Unit, NIHR Southampton Biomedical Research Centre, University of Southampton, Gartnavel General Hospital, Guy's and St Thomas' NHS Foundation Trust, King's College London, Imperial College London

Language: English

Topic: SARS-CoV-2 and COVID-19 Research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,000

Funders: AAIR Charity, Medical Research Council

Award: Preclinical efficacy and safety studies of ADAM33 oligonucleotides as new disease-modifying asthma therapy

OpenAlex ID: W4398248269

FWCI: 1.031

Cites: 10

Cited by: 3

Related to: 10